Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person3
BUSINESS FUNDING RESEARCH LTD (trading as Beauhurst)
Company · 07312969
Iff Research Ltd
Company · 00849983
IVY BUSINESS CENTRE LTD
Company · 08046145
Primary record19
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
NOVAVAX INC filed 8-K
Item 7.01. Regulation FD Information. On October 29, 2026, Novavax, Inc. (“Novavax” or the “Company”) issued a press release announcing the information discussed under Item 8.01 hereof. A copy of the press release is fur
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD: ownership and control
BUSINESS FUNDING RESEARCH LTD (company 07312969), incorporated 2010-07-13, status active. Current officers: AUSTIN, Toby Alexander Spencer (director); BENCE, Stephen John, Dr (director); SONGHURST, Charles (director). Pe
BUSINESS FUNDING RESEARCH LTD (trading as Beauhurst) filed a miscellaneous document. Form RP01SH01, company 07312969.
legacy
UK SHARED BUSINESS SERVICES LIMITED awarded £264,313 to Business Funding Research Ltd
UK SHARED BUSINESS SERVICES LIMITED awarded a contract to Business Funding Research Ltd worth £264,313 on 2025-10-13. Contract: DDaT25272 - UK Companies House and Investment Data. ***** THIS IS AN AWARD NOTICE, NOT A CAL
Derby City Council awarded an undisclosed sum to BUSINESS FUNDING RESEARCH LTD (trading as Beauhurst)
Derby City Council awarded a contract to BUSINESS FUNDING RESEARCH LTD (trading as Beauhurst) on 2026-09-29. Contract: ENQ1375 - Company Information Data Platform. This procurement was conducted via the G-Cloud 14 Framew
BUSINESS FUNDING RESEARCH LTD (trading as Beauhurst) allotted new shares. Form SH01, company 07312969.
capital-allotment-shares
Connect Biopharma Holdings Ltd filed 8-K
Item 7.01 Regulation FD Disclosure. Press Release. On September 30, 2026, Connect Biopharma Holdings Limited (the Company ) issued a press release announcing topline results from its global phase 2 study evaluating radem
Connect Biopharma Holdings Ltd filed 8-K
Item 7.01 Regulation FD Disclosure. Press Release. On September 15, 2026, Connect Biopharma Holdings Limited (the Company ) issued a press release announcing topline results from its global phase 2 study evaluating radem
FLEX LTD. filed SCHEDULE 13G/A
0001274173-26-000199.txt : 20260813 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001274173-23-000073 0001274173 XXXXXXXX LIVE 8 Ordinary Shares 06/30/2026 0000866374 FLEX LTD. Y2573F102 12515-8 RESEARCH BLVD SU
FENNEC PHARMACEUTICALS INC. filed SCHEDULE 13G/A
0001622627-26-000020.txt : 20260813 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001622627-25-000039 0001622627 XXXXXXXX LIVE 3 Common Shares 06/30/2026 0001211583 FENNEC PHARMACEUTICALS INC. 31447P100 PO BOX 1
ICHOR HOLDINGS, LTD. filed SCHEDULE 13G
0001562230-26-000109.txt : 20260812 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001562230 XXXXXXXX LIVE Common Stock 06/30/2026 0001652535 Ichor Holdings, Ltd. G4740B105 3185 LAURELVIEW CT. FREMONT X1 94538 Rule 1